Abstracts
Résumé
L’athérosclérose est la cause majeure des maladies cardiovasculaires et de leurs complications cliniques (accident cérébrovasculaire, infarctus du myocarde). Dans le monde, plus de 16 millions de personnes décèdent chaque année de ces maladies, ce qui représente près d’un tiers de tous les décès. Dans les pays industrialisés, l’athérosclérose, responsable d’environ 50 % des décès, est la première cause de mortalité. Les traitements actuels de cette maladie visent à en maîtriser les facteurs de risque, dont l’un des principaux est le taux élevé de cholestérol plasmatique. Les médicaments les plus efficaces contre l’athérosclérose sont hypocholestérolémiants et appartiennent à la classe des statines. Cependant, les statines diminuent la mortalité due aux maladies cardiovasculaires chez seulement un tiers des patients. De nouveaux produits, susceptibles de diminuer la cholestérolémie ou de ralentir la formation des lésions au niveau de la paroi vasculaire, devraient être développés.
Summary
Atherosclerosis is a disease characterized by lipid accumulation in the vascular wall leading to myocardial infarction or stroke. Hypercholesterolemia is an important risk factor and current treatments are largely based on cholesterol lowering. In spite of proven efficacy of existing drugs, like statins, cardiovascular diseases still remain the most common cause of death in industrialised countries. Many new molecular targets are being studied to improve atherosclerosis treatment and reduce the number of deaths. The action on these targets could lead to a decrease of blood cholesterol levels or produce a direct anti-atherosclerotic effect on the vascular wall. A cholesterol lowering effect could be achieved by reducing cholesterol synthesis (squalene synthase inhibitors), intestinal cholesterol absorption as well as intestinal and liver lipoprotein secretion (microsomal transfer protein inhibitors, acyl-coenzyme A-cholesterol acyltransferase inhibitors) or by increasing fecal excretion of bile acids (ileal sodium-dependent bile acid transporter inhibitors). An anti-atherosclerotic effect on the vascular wall could be achieved by reducing the inflammation via activation of peroxisome proliferator activated receptors, or, more particularly, could consist of decreased expression of adhesion molecules and chemoattractant proteins. Increasing the adenosine triphosphate-binding cassette A1 protein and inhibiting acyl-coenzyme A :cholesterol acyltransferase 1 activity could slow down formation of foam cells, which are a hallmark of atherosclerosis. Finally, the cholesterol fraction carried by high density lipoproteins, which is inversely correlated to cardiovascular risk, could be increased by cholesterol ester transfer protein inhibitors. All of these new classes of compounds are currently studied by pharmaceutical companies and are in different phases of development (preclinical or clinical).
Appendices
Références
- 1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis : Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995 ; 91 : 2488-96.
- 2. Libby P. Changing concepts of atherogenesis. J Intern Med 2000 ; 247 : 349-58.
- 3. Lusis AJ. Atherosclerosis. Nature 2000 ; 407 : 233-41.
- 4. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease : Reducing the risk : The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 1999 ; 19 : 1819-24.
- 5. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium : Triumphs, concerns, and opportunities. N Engl J Med 1997 ; 337 : 1360-9.
- 6. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992 ; 6 : 103-10.
- 7. Ros E. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000 ; 151 : 357-79.
- 8. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998 ; 137 : S101-9.
- 9. Davignon J. Advances in drug treatment of dyslipidemia : Focus on atorvastatin. Can J Cardiol 1998 ; 14 (suppl B) : 28B-38.
- 10. Farnier M, Davignon J. Current and future treatment of hyperlipidemia : The role of statins. Am J Cardiol 1998 ; 82 : 3J-10.
- 11. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials : A meta-analysis. Arch Intern Med 1999 ; 159 : 1793-802.
- 12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 ; 98 : 2088-93.
- 13. van Heek M, Davis H. Pharmacology of ezetimibe. Eur Heart J 2002 ; 4 (suppl) : J5-8.
- 14. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003 ; 107 : 3124-8.
- 15. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002 ; 89 : 11A-7.
- 16. Evans M, Roberts A, Rees A. The future direction of cholesterol-lowering therapy. Curr Opin Lipidol 2002 ; 13 : 663-9.
- 17. Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr Atheroscler Rep 2002 ; 4 : 343-9.
- 18. Brown WV. Therapies on the horizon for cholesterol reduction. Clin Cardiol 2001 ; 24 : III24-7.
- 19. Thompson GR, Naoumova RP. New prospects for lipid-lowering drugs. Exp Opin Invest Drugs 1998 ; 7 : 715-27.
- 20. Pharmaproject. Richmond, Surrey (UK) : PJB Publications, 2003.
- 21. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000 ; 131 : 63-70.
- 22. Chevy F, Illien F, Wolf C, Roux C. Limb malformations of rat fetuses exposed to a distal inhibitor of cholesterol biosynthesis. J Lipid Res 2002 ; 43 : 1192-200.
- 23. Chang G, Ruggeri RB, Harwood HJ, Jr. Microsomal triglyceride transfer protein (MTP) inhibitors : Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Dev 2002 ; 5 : 562-70.
- 24. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001 ; 431 : 127-31.
- 25. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998 ; 137 : 77-85.
- 26. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA : Cholesterol acyltransferase 1. J Clin Invest 2000 ; 105 : 711-9.
- 27. Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA : Cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003 ; 100 : 1262-7.
- 28. Brewer HB Jr. The lipid-laden foam cell : An elusive target for therapeutic intervention. J Clin Invest 2000 ; 105 : 703-5.
- 29. Ichihashi T, Izawa M, Miyata K, et al. Mechanism of hypocholesterolemic action of S-8921 in rats : S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998 ; 284 : 43-50.
- 30. Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000 ; 293 : 315-20.
- 31. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996 ; 97 : 2917-23.
- 32. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 ; 406 : 203-7.
- 33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans : A randomized phase II dose-response study. Circulation 2002 ; 105 : 2159-65.
- 34. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000 ; 289 : 1524-9.
- 35. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002 ; 99 : 7604-9.
- 36. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003 ; 23 : 1169-77.
- 37. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002 ; 22 : 717-26.
- 38. Klappacher GW, Glass CK. Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol 2002 ; 13 : 305-12.
- 39. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002 ; 12 : 2545-8.
- 40. Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 2001 ; 12 : 411-8.